Sept 28 (Reuters) - Australian Clinical Labs Ltd (ACL) :
- SEES H1 FY22 TOTAL REVENUE OF BETWEEN A$398.1 MILLION AND A$414.0 MILLION UPGRADE TO PROSPECTUS FORECAST OF A$307.4 MILLION
- SEES H1 FY22 NPAT BETWEEN A$63 MILLION AND A$70 MILLION
News: ACL Australian Clinical Labs SEES H1 FY22 NPAT Between A$63 MLN And A$70 MLN
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.80 |
Change
-0.020(0.71%) |
Mkt cap ! $548.9M | |||
| Open | High | Low | Value | Volume |
| $2.83 | $2.85 | $2.79 | $1.298M | 461.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 51758 | $2.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.80 | 92945 | 3 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| ACL (ASX) Chart |